BRIEF DESCRIPTION OF DRAWINGS
"The invention is illustrated by the following figures.
"FIG. 1 shows the structural formula of the monomer unit of S. sonnei, phase I bacteria exopolysaccharide.
"FIG. 2 shows C13 NMR-spectrum of S. sonnei, phase I bacteria exopolysaccharide.
"FIG. 3 shows results of GC mass-spectrometry of S. sonnei, phase I bacteria LPS.
"FIG. 4 shows results of GC mass-spectrometry of S. sonnei, phase I bacteria exopolysaccharide; arrows indicate nonhydroxylated fatty acid signals.
"FIG. 5 shows graphs of molecular weight distribution of O-specific polysaccharide, isolated from S.sonnei, phase I bacteria (a) and S.sonnei, phase I bacteria exopolysaccharide (b). In this case, the vertical axis represents the values for ultraviolet absorption at a wavelength of 225 nm; the horizontal axis represents time in minutes.
"FIG. 6 shows graphs of antibody production (15 days) after primary (a) and secondary (b) immunization of mice with preparations made with S. sonnei, phase I bacteria exopolysaccharides (lot 33) and O-polysaccharide from S. sonnei, phase I bacteria LPS, with dose of 25 micrograms per mouse. On the vertical axis are the values for serum titer dilution.
"FIG. 7 shows graphs of binding of antibodies from rabbit monoreceptor serum to S. sonnei, phase I O-antigen, with samples: S. sonnei exopolysaccharide (lot 33 and 35); O-polysaccharide from S. sonnei bacteria LPS; Salmonella enterica sv typhimurium LPS; S. flexneri 2a LPS in ELISA test. On the horizontal axis shows the values of serum titer dilution and the vertical axis--the optical density of reaction color substrate (ortho-phenylenediamine) at a wavelength reading of 495/650 nm.
"FIG. 8 shows a graph of antibody production (15 days) after primary (a) and secondary (b) immunization of mice with vaccine consisting of unconjugated form of S. sonnei, phase I bacterial exopolysaccharide and with vaccine of conjugated with S. sonnei bacteria exopolysaccharide (lot 33) tetanus toxoid (TT), at a dosage of 25 micrograms of exopolysaccharides per mouse. The vertical axis shows values for serum titer dilution.
"FIG. 9 shows graphs of survival rates of two groups of mice, infected with a dose of LD 100 of virulent influenza strain A subtype H1N1. The first group (experimental) received daily injections of the pharmaceutical composition, at a dose of 100 micrograms of exopolysaccharides per mouse, the second group (control)--injections of saline solution."
URL and more information on this patent application, see: Aparin, Petr Gennadievich; Lvov, Vyacheslav Leonidovich; Elkina, Stanislava Ivanovan; Golovina, Marina Eduardovna; Shmigol, Vladimir Igorevich. Exopolysaccharide of Shigella Sonnei Bacteria, Method for Producing Same, Vaccine and Pharmaceutical Composition Containing Same. U.S. Patent Application Serial Number 877305, filed
Keywords for this news article include: Antibodies, Antigens, Patents, Peptides, Shigella, Cell Wall, Treatment, Endotoxins, Immunology, Pediatrics, Amino Acids, Blood Proteins, Immunoglobulins, Bacterial Toxins, Biological Factors, Enterobacteriaceae, Synthetic Vaccines, Cellular Structures, Gammaproteobacteria, Genetic Engineering, Lipopolysaccharides.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
Most Popular Stories
- Slow Week Ahead of December FOMC Meeting
- Hispanics Seek to Grow School Board Members
- U.S. Companies Eager for Iranian Business
- 'Knockout Game': Myth or Menace?
- Questions Remain in Jenni Rivera's Death
- GM Bailout Saved 1.2 Million U.S. Jobs, Report Says
- Bitcoin Used to Buy Tesla Car
- Banks Fret as Volcker Vote Approaches
- Paul Walker Fans Pay Respects
- Yellen Set to Become One of World's Most Powerful Women